Phase II, multicenter, open-label, randomized study of YM155 plus docetaxel as first-line treatment in patients with HER2-negative metastatic breast cancer

Phase Ii ◽

Randomized Study ◽

Metastatic Breast ◽

Line Treatment ◽

First Line ◽

Open Label ◽

A phase II randomized study comparing navelbine and capecitabine (Navcap) followed either by Navcap or by weekly docetaxel in the first-line treatment of HER-2/neu negative metastatic breast cancer

Medical Oncology ◽

10.1007/s12032-010-9754-2 ◽

2010 ◽

Vol 28 (S1) ◽

pp. 142-151 ◽

Cited By ~ 3

Author(s):

M. Ghosn ◽

P. Aftimos ◽

F. S. Farhat ◽

J. G. Kattan ◽

C. Hanna ◽

...

Keyword(s):

Breast Cancer ◽

Phase Ii ◽

Randomized Study ◽

Metastatic Breast ◽

Line Treatment ◽

First Line ◽

Weekly Docetaxel ◽

Her 2 ◽

277 ORAL Interim results of a phase II randomized study of lapatinib (GW572016) as first-line treatment for patients with FISH-amplified advanced or metastatic breast cancer

European Journal of Cancer Supplements ◽

10.1016/s1359-6349(05)80575-0 ◽

2005 ◽

Vol 3 (2) ◽

pp. 78 ◽

Cited By ~ 3

Keyword(s):

Breast Cancer ◽

Phase Ii ◽

Randomized Study ◽

Metastatic Breast ◽

Line Treatment ◽

First Line ◽

Faculty of 1000 evaluation for Bevacizumab plus paclitaxel versus bevacizumab plus capecitabine as first-line treatment for HER2-negative metastatic breast cancer: interim efficacy results of the randomised, open-label, non-inferiority, phase 3 TURANDOT trial.

F1000 - Post-publication peer review of the biomedical literature ◽

10.3410/f.717976445.793471388 ◽

2013 ◽

Author(s):

Ana Maria Gonzalez-Angulo

Keyword(s):

Breast Cancer ◽

Metastatic Breast ◽

Line Treatment ◽

First Line ◽

Open Label ◽

Phase 3 ◽

Exemestane and Chemotherapy as First-line Treatment of Metastatic Breast Cancer: Results of a Phase II Study

Clinical Breast Cancer ◽

10.3816/cbc.2010.n.041 ◽

2010 ◽

Vol 10 (4) ◽

pp. 313-317 ◽

Cited By ~ 3

Author(s):

Juan de la Haba-Rodriguez ◽

Rosario González Mancha ◽

Gumersindo Pérez Manga ◽

Enrique Aranda Aguilar ◽

José Manuel Baena Cañada ◽

...

Keyword(s):

Breast Cancer ◽

Phase Ii ◽

Phase Ii Study ◽

Metastatic Breast ◽

Line Treatment ◽

First Line ◽

A Clinical Phase II Study of a Non-Anthracycline Sequential Combination of Cisplatin-Vinorelbine Followed by Docetaxel as First-Line Treatment in Metastatic Breast Cancer

Oncology ◽

10.1159/000097945 ◽

2006 ◽

Vol 70 (5) ◽

pp. 330-338 ◽

Cited By ~ 2

Author(s):

Ali I. Shamseddine ◽

Zaher K. Otrock ◽

Mohamad J. Khalifeh ◽

Hanan R. Yassine ◽

Maya Charafeddine ◽

...

Keyword(s):

Breast Cancer ◽

Phase Ii ◽

Phase Ii Study ◽

Metastatic Breast ◽

Line Treatment ◽

First Line ◽

Clinical Phase ◽

Sequential Combination ◽

Phase II Trial with Gemcitabine, Paclitaxel and Bevacizumab for the First Line Treatment of Metastatic Breast Cancer.

10.1158/0008-5472.sabcs-09-6089 ◽

2009 ◽

Cited By ~ 2

Author(s):

A. Guardino ◽

M. Chen ◽

M. Levy ◽

C. Chen

Keyword(s):

Breast Cancer ◽

Phase Ii ◽

Phase Ii Trial ◽

Metastatic Breast ◽

Line Treatment ◽

First Line ◽

P5-19-03: Albumin-Bound Paclitaxel (ab-pac) Versus Docetaxel for First-Line Treatment of Metastatic Breast Cancer (MBC): Overall Survival and Safety Analysis of a Randomized Phase II Trial.

10.1158/0008-5472.sabcs11-p5-19-03 ◽

2011 ◽

Cited By ~ 1

Author(s):

WJ Gradishar ◽

D Krasnojon ◽

S Cheporov ◽

AN Makhson ◽

GM Manikhas ◽

...

Keyword(s):

Breast Cancer ◽

Overall Survival ◽

Phase Ii ◽

Phase Ii Trial ◽

Metastatic Breast ◽

Line Treatment ◽

First Line ◽

Randomized Phase Ii ◽

Abstract P5-17-05: Sorafenib plus Ixabepilone as First-Line Treatment for Patients with HER2-Negative Metastatic Breast Cancer: Preliminary Results of the Phase II Trial of the Sarah Cannon Research Institute

10.1158/0008-5472.sabcs12-p5-17-05 ◽

2012 ◽

Author(s):

DA Yardley ◽

J Barton ◽

N Dickson ◽

D Shipley ◽

DR Drosick ◽

...

Keyword(s):

Breast Cancer ◽

Phase Ii ◽

Phase Ii Trial ◽

Metastatic Breast ◽

Line Treatment ◽

First Line ◽

Preliminary Results ◽

First Line Treatment ◽

Research Institute

Abstract OT2-2-01: tnAcity: A phase II/III trial ofnab-paclitaxel (nab-P) plus either gemcitabine (Gem) or carboplatin (Carbo) vs Gem/Carbo as first-line treatment for patients with triple-negative metastatic breast cancer (TNMBC)

10.1158/1538-7445.sabcs14-ot2-2-01 ◽

2015 ◽

Author(s):

Denise A Yardley ◽

Robert E Coleman ◽

Pierfranco Conte ◽

Joyce O'Shaughnessy ◽

Javier Cortes ◽

...

Keyword(s):

Breast Cancer ◽

Phase Ii ◽

Triple Negative ◽

Metastatic Breast ◽

Line Treatment ◽

First Line ◽

Cisplatinum-Based Alternating Non-Cross-Resistant Chemotherapy as a First-Line Treatment in Metastatic Breast Cancer. A Phase II Study

Tumori Journal ◽

10.1177/030089169007600511 ◽

1990 ◽

Vol 76 (5) ◽

pp. 472-475 ◽

Cited By ~ 2

Author(s):

Krsto Kolarić ◽

Rudolf Tomek

Keyword(s):

Breast Cancer ◽

Phase Ii ◽

Phase Ii Study ◽

Metastatic Breast ◽

Line Treatment ◽

First Line ◽